Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 2/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | PPARD | Q03181 | 3/20 | 0.35 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | PPARA | Q07869 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22116308 | 0.95 | PTGDR2 (0.39) | PTGDR2SLC6A2SLC6A4SLC6A3HTT | |
| SCHEMBL22116306 | 0.95 | PTGDR2 (0.39) | PTGDR2SLC6A2SLC6A4SLC6A3HTT | |
| SCHEMBL22116357 | 0.94 | PTGDR2 (0.49) | PTGDR2SLC6A2SLC6A4SLC6A3LMNA | |
| SCHEMBL22116359 | 0.94 | PTGDR2 (0.38) | PTGDR2SLC6A2SLC6A4SLC6A3HTT | |
| SCHEMBL22116418 | 0.94 | PTGDR2 (0.38) | PTGDR2SLC6A2SLC6A4SLC6A3HTT | |
| SCHEMBL22116360 | 0.94 | PTGDR2 (0.38) | PTGDR2SLC6A2SLC6A4SLC6A3HTT | |
| SCHEMBL24234234 | 0.93 | PTGDR2 (0.51) | PTGDR2SLC6A2SLC6A4SLC6A3LMNA | |
| SCHEMBL22116373 | 0.93 | PTGDR2 (0.51) | PTGDR2SLC6A2SLC6A4SLC6A3LMNA | |
| SCHEMBL22116338 | 0.91 | PTGDR2 (0.38) | PTGDR2SLC6A2SLC6A4SLC6A3HTT | |
| SCHEMBL22116415 | 0.91 | PTGDR2 (0.41) | PTGDR2SLC6A2SLC6A4SLC6A3HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3897832-B1 | N-(PYRIDIN-2-YLSULFONYL)CYCLOPROPANECARBOXAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF A CFTR MEDIATED DISEASE | NOVARTIS AG (CH) | 2023-10-11 | — | — | EP | disclosed |
| US-20220033407-A1 | N-(pyridin-2-ylsulfonyl)cyclopropanecarboxamide Derivatives and their Use in the Treatment of Disease | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC. | 2022-02-03 | — | — | US | disclosed |
| EP-3897832-A1 | N-(PYRIDIN-2-YLSULFONYL)CYCLOPROPANECARBOXAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF A CFTR MEDIATED DISEASE | Novartis AG (CH) | 2021-10-27 | — | — | EP | disclosed |
| CN-113226464-A | N- (pyridin-2-ylsulfonyl) cyclopropanecarboxamide derivatives and their use in the treatment of CFTR mediated diseases | 诺华股份有限公司 | 2021-08-06 | — | — | CN | disclosed |
| WO-2020128768-A1 | N-(PYRIDIN-2-YLSULFONYL)CYCLOPROPANECARBOXAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF A CFTR MEDIATED DISEASE | NOVARTIS AG (CH) | 2020-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220033407-A1 | N-(pyridin-2-ylsulfonyl)cyclopropanecarboxamide Derivatives and their Use in the Treatment of Disease | CFTR, PKD2, PKD1 | PTGDR2 192/4885SLC6A2 2535/4885SLC6A4 1941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.